Patient-reported outcomes data from the Phase 3 CheckMate-214 trial of the nivolumab-ipilimumab combination in intermediate- and poor-risk advanced renal cell carcinoma (RCC) patients versus sunitinib show significant benefits in disease-related symptoms and improvements to cancer-related quality of life and well-being.
Patients treated with the nivolumab-ipilimumab combination reported fewer kidney cancer symptoms compared to standard treatment with sunitinib. This finding was significant at all but one post-baseline time point through two years of follow-up.
Time to deterioration was also significantly delayed and patients treated with the nivolumab-ipilimumab combination reported significantly better health-related quality of life with respect to disease-related symptoms, treatment side effects and functioning.
There was a significant and consistent patient reported benefit for the combination compared to standard treatment with sunitinib.
The study was presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago this week.